Print

IAVI A003

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults at Risk of HIV Infection.

Trial Details:

I Ongoing
International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID), Children's Hospital of Philadelphia (CHOP) February 10, 2014
AAV1-PG9 PG9 Antibody
AAV1-PG9 Vectored Immunoprophylaxis
United Kingdom 24
NCT01937455
http://www.clinicaltrials.gov/ct2/show/NCT01937455?term=NCT01937455&rank=1